Emmanuel Antonarakis, MD
Medical Oncology · Minneapolis, MNNPI 1568528768
Payments from drug & device makers
Across 512 payments — averaging $13,381 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2.9M
- Novartis$834K
- Medivation LLC.$721K
- Janssen Research & Development, LLC$624K
- AstraZeneca$475K
- Bayer$352K
- plus $964K from 31 others
Across 1 payment — averaging $3525.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 138 | $2,880,359 |
| Novartis | 7 | $834,266 |
| Medivation LLC. | 20 | $721,427 |
| Janssen Research & Development, LLC | 26 | $623,886 |
| AstraZeneca | 15 | $475,392 |
| Bayer | 65 | $351,939 |
| Macrogenics, Inc. | 40 | $304,113 |
| Dendreon Pharmaceuticals LLC | 8 | $282,067 |
| Pfizer | 63 | $131,955 |
| Seagen Inc. | 15 | $97,397 |
| Astrazeneca UK Limited | 18 | $30,578 |
| Pharmaand GmbH | 4 | $16,201 |
| Sanofi | 12 | $11,726 |
| Janssen Scientific Affairs, LLC | 6 | $10,202 |
| Clovis Oncology, Inc. | 4 | $10,145 |
| Menarini Silicon Biosystems, Inc. | 5 | $10,108 |
| Eli Lilly | 18 | $7,929 |
| Amgen | 8 | $6,201 |
| AbbVie | 11 | $6,009 |
| Blue Earth Diagnostics | 2 | $4,500 |
| E.r. Squibb & Sons, L.L.C. | 5 | $3,909 |
| Myovant Sciences Inc. | 1 | $3,875 |
| Janssen Global Services, LLC | 3 | $3,756 |
| Mylan Inc. | 1 | $3,589 |
| Eisai Inc. | 3 | $3,155 |
| Curium US LLC | 2 | $2,713 |
| Genentech, Inc. | 1 | $2,640 |
| Tolmar, Inc. | 1 | $2,500 |
| Advanced Accelerator Applications | 1 | $2,500 |
| Aadi Bioscience, Inc. | 1 | $1,500 |
| Johnson & Johnson | 2 | $1,391 |
| Telix Pharmaceuticals | 1 | $1,300 |
| GSK | 1 | $650 |
| Corcept Therapeutics | 1 | $500 |
| Partner Therapeutics, Inc. | 1 | $450 |
| Astellas Pharma US Inc | 1 | $126 |
| Genentech USA, Inc. | 1 | $61 |
How this compares
$6,851,015 in reported general payments places this provider in the 90th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Minneapolis
- Amy KrieMinneapolis$2.5M
- Charles RyanMinneapolis$1.6M
- Keith SkubitzMinneapolis$1.1M
- Emil LouMinneapolis$458K
- Edward GreenoMinneapolis$415K
- Evidio Domingo MusibayMinneapolis$281K
- Evanthia GalanisRochester$72.3M
- Frank SinicropeRochester$10.3M
- Harry YoonRochester$10.2M
- Konstantinos LeventakosRochester$9.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.